Med24
metabolic-therapy 10. 11. 2026 • 2 min read • International journal of nanomedicine (PubMed)

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

Knowledge and self-reported practice of laboratory biosafety among medical laboratory professionals in selected public and private hospitals in Mogadishu, Somalia: a cross-sectional study

Insulin resistance represents a significant metabolic issue linked to conditions including type 2 diabetes, obesity, and metabolic syndrome. Techniques are needed to analyze glucose metabolism within tissues. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) provides a noninvasive method for assessing glucose uptake and metabolism.

18F-FDG PET Methodology

Standard 18F-FDG PET relies on factors such as systemic glucose and insulin levels, tracer kinetics, and tissue characteristics, necessitating kinetic modeling for quantification. Nanotechnology has been explored as a means to control tracer delivery, biodistribution, targeting, and imaging capabilities. CT, FDG, MRI, and PET are central to this approach.

Sponsored content

Current Research Landscape

Currently, there is limited experimental data regarding the use of nano-FDG as a quantitative biomarker for insulin resistance. Research in this area primarily comes from fields like oncology, inflammation, nanoparticle design, and multimodal PET/CT and PET/MRI scans. A key limitation is the lack of validation against established metabolic benchmarks, such as the hyperinsulinemic-euglycemic clamp method. The review examines existing literature on 18F-FDG-based nanotechnology platforms, glucose-labeled nanoparticles, and radioactively labeled nanomaterials. It assesses the available evidence concerning the application of these technologies for evaluating nanoparticle-based therapies, considering both direct and indirect evidence related to assessing insulin resistance.

Original Scientific Source
International journal of nanomedicine (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement